Max Robotics — Global Service Robot Directory + US Certification

About

Anthony A. Kossiakoff is a pioneer in the development of high-throughput, recombinant antibody technologies, fundamentally transforming how researchers generate and use these critical reagents. His work has centered on creating industrialized platforms for producing renewable, high-quality antibodies, directly addressing the limitations of traditional monoclonal methods. A landmark contribution is his 2015 paper detailing a platform that generated validated recombinant antibodies for 346 transcription factors, a feat that has garnered over 120 citations and exemplifies his impact on scalable proteomics. Kossiakoff’s research also advanced phage-displayed synthetic antibody libraries, enabling rapid, cost-effective selection for both basic and clinical applications. His innovations have made it possible to produce permanent, renewable antibody resources, eliminating the variability of commercial sources. With a career focused on bridging the gap between demand and supply in antibody production, Kossiakoff’s work has been instrumental in empowering large-scale biological studies and accelerating discovery in molecular biology and medicine.